Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

CHANGE OF SECRETARY TO THE BOARD AND JOINT COMPANY SECRETARY

This announcement is made by Beijing Biostar Pharmaceuticals Co., Ltd. (the "**Company**").

The board (the "**Board**") of directors (the "**Directors**") of the Company announces that, as the Company has decided not to renew the employment contract with Mr. Liu Kailin ("**Mr. Liu**"), Mr. Liu will cease to hold any senior management position or any other position with the Company. Accordingly, the Board has resolved that Mr. Liu shall cease to act as the secretary to the Board and a joint company secretary of the Company, with effect from 10 November 2026. Mr. Chan Yik Pun will continue to act as the other joint company secretary of the Company.

As of the date of this announcement, Mr. Liu has completed all relevant handover procedures and has not expressed any disagreement on the change of the secretary to the Board and joint company secretary of the Company.

The Board would like to express its sincere gratitude to Mr. Liu for his contributions and efforts during his tenure as the secretary to the Board and a joint company secretary of the Company.

Following the cessation of office of Mr. Liu, the Board has resolved that Dr. Qiu Rongguo shall: (1) act as the secretary to the Board. The acting appointment in respect of the duties of the secretary to the Board shall take effect from the date of this announcement; (2) act as a joint company secretary, but this resolution shall take effect from the date on which the waiver application submitted pursuant to Rules 3.28 and 8.17 of the Listing Rules is approved by the Stock Exchange.

The Board also confirms that the above change will not have any material impact on the normal operations and management of the Company, and there are no other matters that need to be brought to the attention of the Stock Exchange or the shareholders of the Company.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairman and Executive Director

Beijing, the PRC, 10 November 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Mr. Shiu Shu Ming, Dr. Ye Chengang and Dr. Zhu Xiaodong as independent non-executive Directors.